ArticleScientific reports2026
TRIM31 inhibits ferroptosis in LUAD through facilitating ubiquitination and degradation of P53.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Lung cancer (LC) causes large amount of cancer death worldwide. As the most common and aggressive type of LC, the molecular mechanisms in LUAD (Lung Adenocarcinoma) remain unclear. In order to find novel potential molecular targets for improving the prognosis of LUAD, we obtained gene information of LUAD patients from The Cancer Genome Atlas (TCGA) and identified hub genes through weighted gene co-expression network analysis (WGCNA). We selected the top 25% of total 5945 differently expressed genes (DEGs) and established 16 modules. The purple module was highly associated with tumor stage and chosen as key module. Further analysis revealed that the level of 6 hub genes (TRIM31, DKK1, FAM83A, RHOV, S100P and TSKU) were negatively relevant to survival rate but positively correlated with advanced tumor stage. Immunohistochemistry (IHC), western blot (WB) and reverse transcription-quantitative PCR (RT-qPCR) verified the high expression of TRIM31 in LUAD. Loss-of-function assays indicated TRIM31 accelerated viability, proliferation and metastasis of LUAD cells. According to the UbiBrowser website, TRIM31, as an E3 ubiquitin ligase, may be involved in the ubiquitination of P53, an important tumor suppressor. Co-immunoprecipitation verified the interaction between TRIM31 and P53. More importantly, the degradation rate of P53 was slowed when TRIM31 was knockdown. Further immunoblot assays revealed that TRIM31 promoted the ubiquitination and degradation of P53. P53 could inhibit the expression of SLC7A11 and was regarded as an important regulator of ferroptosis. Ferroptosis analysis showed that TRIM31 knockdown decreased cell viability and GSH, but increased ROS, MDA and iron, which could reverse by knockdown of P53. Above results displayed that TRIM31 effected ferroptosis level via P53. In addition, website prediction showed that BATF was a transcription factor of TRIM31, and experiments confirmed that BATF could indeed promote the transcription of TRIM31. Taken together, the data demonstrated that TRIM31 promoted LUAD progression by inhibiting ferroptosis via the TRIM31/P53/SLC7A11 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.